Here is a statement from our Chief Executive, Paula Chadwick:
We welcome the decision from NICE to recommend Crizotinib for advanced non- small cell lung cancer.
Crizotinib represents a clear advance in treatment options for patients living with advanced lung cancer.
In 2013, lung cancer had the lowest share of research funding across the big four cancers at 6%. Since this finding, we have campaigned hard for more investment into research and treatment for patients living with lung cancer.
Today’s decision is a positive endorsement of this campaign and we applaud the NHS, Nice and Pfizer.
We hope to see many more positive decisions and continued investment as we move one step closer to beating the UK’s biggest cancer killer.”